Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anus Neoplasms | 2 | 2018 | 38 | 1.180 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 656 | 0.830 |
Why?
|
| Melanoma | 3 | 2017 | 828 | 0.830 |
Why?
|
| Sentinel Lymph Node | 1 | 2017 | 7 | 0.590 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 104 | 0.560 |
Why?
|
| Lymph Nodes | 3 | 2017 | 376 | 0.490 |
Why?
|
| Preoperative Care | 2 | 2020 | 350 | 0.470 |
Why?
|
| Skin Neoplasms | 2 | 2011 | 801 | 0.460 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2022 | 153 | 0.440 |
Why?
|
| Pancreatic Neoplasms | 4 | 2022 | 685 | 0.420 |
Why?
|
| Pancreatectomy | 5 | 2022 | 137 | 0.420 |
Why?
|
| Dactinomycin | 1 | 2011 | 67 | 0.390 |
Why?
|
| Melphalan | 1 | 2011 | 49 | 0.390 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 1217 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1237 | 0.310 |
Why?
|
| Postoperative Complications | 4 | 2020 | 3052 | 0.300 |
Why?
|
| Gallbladder Neoplasms | 2 | 2018 | 14 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2019 | 355 | 0.290 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 402 | 0.290 |
Why?
|
| Tumor Burden | 2 | 2018 | 229 | 0.280 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1124 | 0.250 |
Why?
|
| Aged | 17 | 2020 | 19406 | 0.250 |
Why?
|
| Colonic Neoplasms | 2 | 2018 | 247 | 0.240 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 267 | 0.230 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2004 | 95 | 0.220 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2018 | 142 | 0.200 |
Why?
|
| Middle Aged | 15 | 2020 | 26384 | 0.190 |
Why?
|
| Retrospective Studies | 13 | 2022 | 16223 | 0.190 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2019 | 27 | 0.180 |
Why?
|
| Lymph Node Excision | 2 | 2018 | 157 | 0.180 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 35 | 0.170 |
Why?
|
| Resource Allocation | 1 | 2020 | 52 | 0.170 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2020 | 33 | 0.170 |
Why?
|
| Parathyroidectomy | 1 | 2020 | 49 | 0.170 |
Why?
|
| Coloring Agents | 1 | 2020 | 78 | 0.170 |
Why?
|
| Intraoperative Care | 1 | 2020 | 104 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 326 | 0.170 |
Why?
|
| Indocyanine Green | 1 | 2020 | 59 | 0.170 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 158 | 0.160 |
Why?
|
| Nutrition Assessment | 1 | 2020 | 136 | 0.160 |
Why?
|
| Thrombosis | 1 | 2004 | 520 | 0.160 |
Why?
|
| Ureter | 1 | 2020 | 95 | 0.160 |
Why?
|
| Survival Rate | 3 | 2018 | 2018 | 0.160 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2004 | 448 | 0.150 |
Why?
|
| Cholecystectomy | 1 | 2018 | 56 | 0.150 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 181 | 0.150 |
Why?
|
| Hernia, Abdominal | 1 | 2018 | 18 | 0.150 |
Why?
|
| Colorectal Neoplasms | 1 | 2004 | 565 | 0.150 |
Why?
|
| Male | 17 | 2022 | 60910 | 0.150 |
Why?
|
| Anal Canal | 1 | 2018 | 79 | 0.150 |
Why?
|
| Patient Care Planning | 1 | 2019 | 122 | 0.150 |
Why?
|
| Malnutrition | 1 | 2020 | 203 | 0.140 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2017 | 23 | 0.140 |
Why?
|
| Humans | 22 | 2022 | 124311 | 0.140 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 115 | 0.140 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 6450 | 0.140 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2017 | 95 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2018 | 119 | 0.140 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 79 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 285 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 107 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 110 | 0.130 |
Why?
|
| Drainage | 1 | 2017 | 257 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 216 | 0.120 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 265 | 0.120 |
Why?
|
| Female | 15 | 2020 | 66312 | 0.120 |
Why?
|
| Decision Making | 1 | 2020 | 656 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2019 | 12278 | 0.120 |
Why?
|
| Hospitals | 1 | 2017 | 395 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 605 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 357 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 373 | 0.120 |
Why?
|
| Adult | 7 | 2019 | 29374 | 0.110 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 199 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2018 | 1174 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2018 | 502 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1101 | 0.100 |
Why?
|
| Genital Neoplasms, Female | 1 | 2012 | 46 | 0.100 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2011 | 7 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 79 | 0.100 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2011 | 54 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 152 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 997 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 725 | 0.090 |
Why?
|
| Young Adult | 4 | 2019 | 8955 | 0.080 |
Why?
|
| Pancreatic Fistula | 1 | 2008 | 29 | 0.070 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 36 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2011 | 950 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 2414 | 0.070 |
Why?
|
| Length of Stay | 1 | 2011 | 1306 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 4729 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2017 | 1479 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1317 | 0.050 |
Why?
|
| Posture | 1 | 2004 | 152 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 1603 | 0.050 |
Why?
|
| Proteins | 1 | 2008 | 1042 | 0.050 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2022 | 92 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 2498 | 0.040 |
Why?
|
| Parathyroid Hormone | 1 | 2020 | 72 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2020 | 3371 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1675 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 5096 | 0.040 |
Why?
|
| Fascia | 1 | 2018 | 15 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2020 | 312 | 0.040 |
Why?
|
| Colon, Ascending | 1 | 2018 | 8 | 0.040 |
Why?
|
| Colon, Sigmoid | 1 | 2018 | 13 | 0.040 |
Why?
|
| Neomycin | 1 | 2018 | 37 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 3080 | 0.040 |
Why?
|
| Cathartics | 1 | 2018 | 27 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 28 | 0.040 |
Why?
|
| Citric Acid | 1 | 2018 | 36 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 108 | 0.040 |
Why?
|
| Metronidazole | 1 | 2018 | 155 | 0.040 |
Why?
|
| Operative Time | 1 | 2018 | 166 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 279 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2018 | 199 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 668 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2018 | 676 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 606 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1018 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 860 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1155 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1416 | 0.030 |
Why?
|
| United States | 2 | 2020 | 10756 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1244 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2012 | 27 | 0.030 |
Why?
|
| Registries | 1 | 2018 | 1411 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2017 | 638 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 19310 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 4548 | 0.020 |
Why?
|
| Pancreaticojejunostomy | 1 | 2008 | 6 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 6259 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2017 | 6087 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 2812 | 0.020 |
Why?
|
| Risk Factors | 1 | 2012 | 10124 | 0.010 |
Why?
|